Artificial intelligence specialist Scipher Medicine has signed an inflammatory bowel disease collaboration with Galapagos that exemplifies what Scipher is hoping to establish as its business model – repurposing the AI it uses to sift through mountains of clinical-genomic patient data for its diagnostics business to also identify novel targets that may lead to drug therapies for non-responding patients. [Editor's note: This article has been corrected to note that Scipher's patient data are not derived from clinical trials.]
Scipher’s primary business is developing blood tests to enable clinicians to determine which autoimmune disease patients likely will or won’t...
Welcome to Scrip
Create an account to read this article
Already a subscriber?
